Navigation Links
Upsher-Smith To Present New Research On USL255 (Extended-Release Topiramate) At 2013 American Epilepsy Society Annual Meeting
Date:11/18/2013

MAPLE GROVE, Minn., Nov. 18, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that it will present new research from its epilepsy clinical development program for USL255 (extended-release topiramate) during the American Epilepsy Society's (AES) 67th Annual Meeting in Washington, DC, December 6-10, 2013.  

(Logo:  http://photos.prnewswire.com/prnh/20130520/NY17281LOGO)

Seven presentations will highlight results from the PREVAIL clinical trial, the first of its kind conducted on an extended-release formulation of topiramate.  The global Phase 3 study enrolled more than 200 patients and assessed the efficacy and safety of USL255 as an adjunctive treatment of epilepsy in patients with refractory partial-onset seizures (POS).  In addition, two presentations will feature Phase 1 findings including the pharmacokinetics of USL255 when sprinkled onto food or swallowed intact and the impact of delayed-dose administration of USL255.

USL255 is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.  It is being developed by Upsher-Smith for the management of seizure disorders.  Upsher-Smith's New Drug Application for USL255 has been accepted for review by the U.S. Food and Drug Administration (FDA).

"This year's AES meeting marks the first time the findings from our Phase 3 trial will be presented publicly," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith.  "We look forward to sharing data from the first global Phase 3 clinical trial of an extended-release formulation of topiramate with the epilepsy community at this year's Annual Meeting." 

Poster Presentations

PREVAIL Phase 3 Clinical Trial

USL255 Phase 1

Abstracts of the poster presentations can be found online at www.aesnet.org.  To schedule an interview with an investigator, please contact Elizabeth Likly at elikly@klcpr.com.  

About Upsher-Smith's Phase 3 (PREVAIL) Clinical Trial

The PREVAIL trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory POS. 

PREVAIL was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.  More information about the trial is available at www.clinicaltrials.gov (NCT01142193).

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in patients with refractory POS who had participated in PREVAIL is ongoing.  The open-label extension study can be found by searching NCT01191086 on www.clinicaltrials.gov.

Upsher-Smith's Epilepsy Pipeline

Upsher-Smith's clinical development pipeline includes three investigational drugs that are being studied for the management of seizure disorders.  USL255 is an investigational once-daily, extended-release topiramate for the management of epilepsy.  The pipeline also includes USL261, an investigational intranasal midazolam for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters, which is the subject of an ongoing international Phase 3 clinical trial (ARTEMIS1) with an open-label safety extension study.  In addition, USL260 (tonabersat) is in early clinical development as a potential first-in-class neuronal gap junction modulator.

About Upsher-Smith

Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit www.upsher-smith.com.

 


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
2. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
3. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
4. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
5. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
6. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Upsher-Smith Introduces Newly Redesigned Corporate Website
10. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
11. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  John Seng, founder of ... will succeed him as Chief Executive Officer following two consecutive years ... Wilson joined Spectrum as president in 2014 and assumed management of ... received public relations industry recognition as Healthcare Agency of the Year ... ...
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated to reach USD ... Research, Inc. Evolution of prenatal testing in the form of noninvasive tests ... diagnostic testing to determine the likelihood of fetal abnormality is expected to ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... , ... December 04, 2016 , ... ... that have new attractive animation styles with unique displacement design elements," said Christina ... pre-animated lower third designs. Choose from a variety of design styles that include ...
(Date:12/4/2016)... PITTSBURGH, PA (PRWEB) , ... December 04, 2016 , ... ... not enough. One must brush properly to achieve optimal results. This important necessity inspired ... saw a need for a way to ensure that people break or avoid bad ...
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s ... help provide scholarship funds for area students and operating support to UNCF-member institutions, ...
Breaking Medicine News(10 mins):